{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:57:56Z","timestamp":1773154676120,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T00:00:00Z","timestamp":1400198400000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To compare the efficacy and safety of infliximab-biosimilar with other biological drugs for the treatment of active ankylosing spondylitis (AS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Systematic literature review for randomized controlled trials (RCTs) with adalimumab, etanercept, golimumab, infliximab and infliximab-biosimilar in AS was performed and indirect meta-analysis (Bayesian mixed treatment comparison) was carried out. The proportion of patients reaching 20\u00a0% improvement by the assessment of Spondyloarthritis International Society response criteria (ASAS20) at weeks 12 and 24 was used as efficacy endpoints, and the occurrence of serious adverse events at week 24 was applied to compare the safety of the biologicals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Altogether, 13 RCTs, identified by the systematic literature search, were included in the analysis. Results on the ASAS20 efficacy endpoint were reported for week 12 in 12 RCTs involving 2,395 patients, and for week 24 in 5 RCTs comprising 1,337 patients. All the five biological agents proved to be significantly superior to placebo. Infliximab showed the highest odds ratio (OR) of 7.2 (95\u00a0% CI 3.68\u201313.19) compared to placebo, followed by infliximab-biosimilar with OR 6.25 (95\u00a0% CI 2.55\u201313.14), both assessed at week 24. No significant difference was found between infliximab-biosimilar and other biological treatments regarding their efficacy and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first study which includes a biosimilar drug in the meta-analysis of biological treatments in AS. The results have proven the similar efficacy and safety profile of infliximab-biosimilar treatment compared to other biologicals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-014-0593-5","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T15:56:12Z","timestamp":1400169372000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Petra","family":"Baji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"P\u00e9ntek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ndor","family":"Sz\u00e1nt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e1l","family":"G\u00e9her","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Gul\u00e1csi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Brodszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"593_CR1","doi-asserted-by":"publisher","unstructured":"P\u00e9ntek, M., Po\u00f3r, Gy., Wiland, P., Martina, O., Brzosko, M., Codrenau, C., Brodszky, N., Gul\u00e1csi, L.: Biologic therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur. J. Health Econ. (2014). doi:10.1007\/s10198-014-0592-6","DOI":"10.1007\/s10198-014-0592-6"},{"issue":"10","key":"593_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., Mikazane, H., Gutierrez-Urena, S., Lim, M., Lee, Y.A., Lee, S.J., Kim, H., Yoo, D.H., Braun, J.: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72(10), 1605\u20131612 (2013)","journal-title":"Ann. Rheum. Dis."},{"key":"593_CR3","doi-asserted-by":"crossref","unstructured":"Sieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos-Vargas, R., Dougados, M., Hermann, K.G., Landewe, R., Maksymowych, W., van der Heijde, D.: The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 68(Suppl 2), ii1\u2013ii44 (2009)","DOI":"10.1136\/ard.2008.104018"},{"issue":"3","key":"593_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3111\/13696998.2012.660255","volume":"15","author":"A Migliore","year":"2012","unstructured":"Migliore, A., Broccoli, S., Bizzi, E., Lagana, B.: Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials. J. Med. Econ. 15(3), 473\u2013480 (2012)","journal-title":"J. Med. Econ."},{"issue":"1","key":"593_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","volume":"24","author":"AE Ades","year":"2006","unstructured":"Ades, A.E., Sculpher, M., Sutton, A., Abrams, K., Cooper, N., Welton, N., Lu, G.: Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 24(1), 1\u201319 (2006)","journal-title":"Pharmacoeconomics"},{"issue":"20","key":"593_CR6","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu, G., Ades, A.E.: Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105\u20133124 (2004)","journal-title":"Stat. Med."},{"key":"593_CR7","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Green, S.: Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration (2009)","DOI":"10.1002\/9780470712184"},{"key":"593_CR8","doi-asserted-by":"crossref","unstructured":"McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., Hill, R.A., Jones, A., Mujica Mota, R., Walley, T.: Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol. Assess. 11(28), 1\u2013158 (iii\u2013iv) (2007)","DOI":"10.3310\/hta11280"},{"issue":"4","key":"593_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden, S., Valkenburg, H.A., Cats, A.: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27(4), 361\u2013368 (1984)","journal-title":"Arthritis Rheum."},{"key":"593_CR10","doi-asserted-by":"publisher","unstructured":"Baji, P., P\u00e9ntek, M., Czirj\u00e1k, L., Szekanecz, Z., Nagy, Gy., Gul\u00e1csi, L., Brodszky, V.: Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis; a mixed treatment comparison. Eur. J. Health Econ. Suppl. (2014). doi:10.1007\/s10198-014-0594-4","DOI":"10.1007\/s10198-014-0594-4"},{"issue":"1","key":"593_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., McQuay, H.J.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1\u201312 (1996)","journal-title":"Control. Clin. Trials"},{"issue":"3","key":"593_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang, F., Gu, J., Zhu, P., Bao, C., Xu, J., Xu, H., Wu, H., Wang, G., Shi, Q., Andhivarothai, N., Anderson, J., Pangan, A.L.: Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann. Rheum. Dis. 73(3), 587\u2013594 (2014)","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"593_CR13","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D., Da Silva, J.C., Dougados, M., Geher, P., van der Horst-Bruinsma, I., Juanola, X., Olivieri, I., Raeman, F., Settas, L., Sieper, J., Szechinski, J., Walker, D., Boussuge, M.P., Wajdula, J.S., Paolozzi, L., Fatenejad, S.: Etanercept 50\u00a0mg once weekly is as effective as 25\u00a0mg twice weekly in patients with ankylosing spondylitis. Ann. Rheum. Dis. 65(12), 1572\u20131577 (2006)","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"593_CR14","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/ard.2009.121327","volume":"69","author":"N Barkham","year":"2010","unstructured":"Barkham, N., Coates, L.C., Keen, H., Hensor, E., Fraser, A., Redmond, A., Cawkwell, L., Emery, P.: Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann. Rheum. Dis. 69(11), 1926\u20131928 (2010)","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"593_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados, M., Braun, J., Szanto, S., Combe, B., Elbaz, M., Geher, P., Thabut, G., Leblanc, V., Logeart, I.: Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann. Rheum. Dis. 70(5), 799\u2013804 (2011)","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"593_CR16","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman, R.D., Davis Jr, J.C., Heijde, D., Diekman, L., Sieper, J., Kim, S.I., Mack, M., Han, J., Visvanathan, S., Xu, Z., Hsu, B., Beutler, A., Braun, J.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58(11), 3402\u20133412 (2008)","journal-title":"Arthritis Rheum."},{"issue":"6","key":"593_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","volume":"37","author":"RD Inman","year":"2010","unstructured":"Inman, R.D., Maksymowych, W.P.: A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J. Rheumatol. 37(6), 1203\u20131210 (2010)","journal-title":"J. Rheumatol."},{"issue":"11","key":"593_CR18","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo-Ortega","year":"2005","unstructured":"Marzo-Ortega, H., McGonagle, D., Jarrett, S., Haugeberg, G., Hensor, E., O\u2019Connor, P., Tan, A.L., Conaghan, P.G., Greenstein, A., Emery, P.: Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann. Rheum. Dis. 64(11), 1568\u20131575 (2005)","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"593_CR19","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D., Kivitz, A., Schiff, M.H., Sieper, J., Dijkmans, B.A., Braun, J., Dougados, M., Reveille, J.D., Wong, R.L., Kupper, H., Davis Jr, J.C.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136\u20132146 (2006)","journal-title":"Arthritis Rheum."},{"key":"593_CR20","first-page":"505","volume":"52","author":"W Maksymowych","year":"2005","unstructured":"Maksymowych, W., Rahman, P., Keystone, E., Wong, R.L., Inman, R.: Efficacy of adalimumab in active ankylosing spondylitis (AS)\u2014results of the Canadian AS study. Arthritis Rheum. 52, 505 (2005)","journal-title":"Arthritis Rheum."},{"issue":"18","key":"593_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman, J.D., Sack, K.E., Davis Jr, J.C.: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346(18), 1349\u20131356 (2002)","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"593_CR22","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin, A., Dijkmans, B.A., Emery, P., Hakala, M., Kalden, J., Leirisalo-Repo, M., Mola, E.M., Salvarani, C., Sanmarti, R., Sany, J., Sibilia, J., Sieper, J., van der Linden, S., Veys, E., Appel, A.M., Fatenejad, S.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. 63(12), 1594\u20131600 (2004)","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"593_CR23","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis Jr, J.C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D.O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48(11), 3230\u20133236 (2003)","journal-title":"Arthritis Rheum."},{"issue":"9313","key":"593_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-Ihle, E., Kellner, H., Krause, A., Schneider, M., Sorensen, H., Zeidler, H., Thriene, W., Sieper, J.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313), 1187\u20131193 (2002)","journal-title":"Lancet"},{"issue":"2","key":"593_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., Braun, J.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52(2), 582\u2013591 (2005)","journal-title":"Arthritis Rheum."},{"issue":"6","key":"593_CR26","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sorensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., Braun, J.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48(6), 1667\u20131675 (2003)","journal-title":"Arthritis Rheum."},{"issue":"10","key":"593_CR27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.clinthera.2010.09.003","volume":"32","author":"EG Boyce","year":"2010","unstructured":"Boyce, E.G., Halilovic, J., Stan-Ugbene, O.: Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin. Ther. 32(10), 1681\u20131703 (2010)","journal-title":"Clin. Ther."},{"issue":"4","key":"593_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/14740338.2011.581661","volume":"10","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy, D., Rudwaleit, M.: Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Expert Opin. Drug Saf. 10(4), 655\u2013673 (2011)","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"593_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00590-012-1035-7","volume":"23","author":"ZH Li","year":"2013","unstructured":"Li, Z.H., Zhang, Y., Wang, J., Shi, Z.J.: Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur. J. Orthop. Surg. Traumatol. 23(5), 497\u2013506 (2013)","journal-title":"Eur. J. Orthop. Surg. Traumatol."},{"key":"593_CR30","unstructured":"Thaler, K.J., Gartlehner, G., Kien, C., Van Noord, M.G., Thakurta, S., Wines, R.C.M., Hansen, R.A., McDonagh, M.S.: Drug class review: targeted immune modulators: final update 3 report [Internet]. http:\/\/pharmacy.oregonstate.edu\/drug_policy\/sites\/default\/files\/pages\/dur_board\/reviews\/articles\/2012_06_28_TIMS_executive.pdf (2012)"},{"issue":"5","key":"593_CR31","first-page":"717","volume":"31","author":"T Shu","year":"2013","unstructured":"Shu, T., Chen, G.H., Rong, L., Feng, F., Yang, B., Chen, R., Wang, J.: Indirect comparison of anti-TNF-alpha agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin. Exp. Rheumatol. 31(5), 717\u2013722 (2013)","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl 11","key":"593_CR32","first-page":"S47","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling, J.: Measures of symptoms and disease status in ankylosing spondylitis: ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 63(Suppl 11), S47\u2013S58 (2011)","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-014-0593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-014-0593-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-014-0593-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-014-0593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T10:01:36Z","timestamp":1735725696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-014-0593-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":32,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1007\/s10198-014-0593-5","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"4 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}